Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer

被引：5
|
作者：
Knoedler, M.
Gauler, T. C.
Matzdorff, A.
Dietz, A.
Gruenwald, V.
Arnold, D.
Hennemann, B.
Schroeder, M.
Hofele, C.
Schmittel, A.
Keilholz, U.
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Univ Klinikum Essen, Essen, Germany
[3] Caritasklin, Saarbrucken, Germany
[4] Univ Klinikum Leipzig, Leipzig, Germany
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] Univ Klinikum Halle, Halle, Germany
[7] Univ Klinikum Regensburg, Regensburg, Germany
[8] St Johannes Hosp Duisburg, Duisburg, Germany
[9] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.6066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6066
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Bhatia, Aarti
    Mehra, Ranee
    Bauman, Jessica
    Khan, Saad A.
    Wei, Wei
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Alpaugh, R. Katherine
    Lango, Miriam
    Rimm, David L.
    Ridge, John A.
    Burtness, Barbara
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
  • [22] Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer
    Guntinas-Lichius, O
    Appenrodt, S
    Veelken, F
    Krug, B
    LARYNGOSCOPE, 2006, 116 (04): : 613 - 618
  • [23] Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
    Forster, Martin D.
    Dillon, Magnus T.
    Kocsis, Judit
    Remenar, Eva
    Pajkos, Gabor
    Rolland, Frederic
    Greenberg, Jonathan
    Harrington, Kevin J.
    EUROPEAN JOURNAL OF CANCER, 2019, 123 : 36 - 47
  • [24] Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Gilbert, Jill
    Cmelak, Anthony
    Shyr, Yu
    Netterville, James
    Burkey, Brian B.
    Sinard, Robert J.
    Yarbrough, Wendall G.
    Chung, Christine H.
    Aulino, Joseph M.
    Murphy, Barbara A.
    CANCER, 2008, 113 (01) : 186 - 192
  • [25] Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
    Hannah Fuchs
    Johannes Pammer
    Christoph Minichsdorfer
    Doris Posch
    Gabriela Kornek
    Marie-Bernadette Aretin
    Thorsten Fuereder
    Medical Oncology, 2018, 35
  • [26] A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Kochanny, Sara E.
    Worden, Francis P.
    Adkins, Douglas R.
    Lim, Dean W.
    Bauman, Julie E.
    Wagner, Stephanie A.
    Brisson, Ryan J.
    Karrison, Theodore G.
    Stadler, Walter M.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    CANCER, 2020, 126 (10) : 2146 - 2152
  • [27] Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
    Bauman, Julie E.
    Saba, Nabil F.
    Roe, Denise
    Bauman, Jessica R.
    Kaczmar, John
    Bhatia, Aarti
    Muzaffar, Jameel
    Julian, Ricklie
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor
    Giri, Anshu
    Burtness, Barbara
    Centuori, Sara
    Caulin, Carlos
    Klein, Robert
    Saboda, Kathylynn
    Obara, Stefanie
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3851 - +
  • [28] Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
    Fuchs, Hannah
    Pammer, Johannes
    Minichsdorfer, Christoph
    Posch, Doris
    Kornek, Gabriela
    Aretin, Marie-Bernadette
    Fuereder, Thorsten
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [29] Phase II study of oral S-1 in pretreated patients with recurrent or metastatic head and neck cancer
    Park, S.
    Lee, S.
    Park, J.
    Cho, E.
    Shin, D.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody
    Koyama, T.
    Kiyota, N.
    Boku, S.
    Imamura, Y.
    Shibata, N.
    Satake, H.
    Tanaka, K.
    Hayashi, H.
    Onoe, T.
    Asada, Y.
    Yamazaki, T.
    Nose, T.
    Ohata, S.
    Nagatani, Y.
    Kimbara, S.
    Funakoshi, Y.
    Teshima, M.
    Shinomiya, H.
    Minami, H.
    ESMO OPEN, 2024, 9 (06)
12345